The utility of anti-PD-1/PD-L1 immunotherapy in EGFR-mutated tumours has been investigated in several trials (Table 3), which consistently showed that NSCLC tumours with EGFR mutations have a poor response to these therapies. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.